Showing results (201-210 of 212) with videos related to
Sort By:
Pageof 22
Signal Transduction and Targeted Therapy|December 17, 2024
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 studyHongkai Wang, Shusuan Jiang, Hong Luo, et al.The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.Plos One|June 20, 2015
Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/mlRui Chen, Yiran Huang, Xiaobing Cai, et al.Cancer Biology & Medicine|February 6, 2024
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancerNanhui Chen, Zengjun Wang, Ming Chen, et al.BJU International|September 17, 2025
A structured training curriculum for robot-assisted radical nephroureterectomy: a Delphi consensus studyFarshad Sheybaee Moghaddam, Alireza Ghoreifi, Rashid K Sayyid, et al.Journal of Zhejiang University. Science. B|September 23, 2025
A practice guideline for therapeutic drug monitoring of mycophenolic acid for solid organ transplantsShuang Liu, Hongsheng Chen, Zaiwei Song, et al.Frontiers in Pharmacology|March 7, 2022
Hengli<sup>®</sup> Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled TrialLimin Liao, Qinggang Liu, Huiling Cong, et al.European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.Asian Journal of Urology|March 8, 2018
Prostate cancer in Asia: A collaborative reportRui Chen, Shancheng Ren, , et al.Pageof 22